True... Except this is EUA and the longer the review goes, the less likely authorization will be granted. The FDA is at 88 days and counting, clearly they don't see an urgency in approving Lenz for "Emergency" use.
Has anyone noticed that analysts have slashed their earnings estimates? I wonder why...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.